NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

NCT04539808 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma
Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8
Stage I Pancreatic Cancer American Joint Committee on Cancer v8
Stage III Pancreatic Cancer American Joint Committee on Cancer v8
Stage IV Pancreatic Cancer American Joint Committee on Cancer v8

Interventions

DRUG: Capecitabine
DRUG: Fluorouracil
DRUG: Irinotecan Hydrochloride
DRUG: Leucovorin Calcium
DRUG: Losartan Potassium
DRUG: Oxaliplatin
RADIATION: Radiation Therapy
PROCEDURE: Resection
PROCEDURE: Diagnostic Imaging
PROCEDURE: Biospecimen Collection
DRUG: Gemcitabine
DRUG: Nab paclitaxel

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]